{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:24:53Z","timestamp":1770488693091,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.antiviral.2017.12.001","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T22:40:04Z","timestamp":1512513604000},"page":"9-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries"],"prefix":"10.1016","volume":"150","author":[{"given":"Hakan","family":"Leblebicioglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joop E.","family":"Arends","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Resat","family":"Ozaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampaolo","family":"Corti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lurdes","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Boesecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Ustianowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Sofi","family":"Duberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Ruta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nermin N.","family":"Salkic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Husa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Lazarevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan A.","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia Yurievna","family":"Pshenichnaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tengiz","family":"Tsertswadze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojca","family":"Mati\u010di\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmond","family":"Puca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulzhan","family":"Abuova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Gervain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin","family":"Bayramli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salih","family":"Ahmeti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mairi","family":"Koulentaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Badreddine","family":"Kilani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Vince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Negro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Sunbul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2017.12.001_bib1","unstructured":"(access-to-hepatitis-C-treatment\/page\/3060907\/\">http:\/\/www.aidsmap.com\/France-to-provide-universal-access-to-hepatitis-C-treatment\/page\/3060907\/) (accessed at 1 July 2016)."},{"issue":"5","key":"10.1016\/j.antiviral.2017.12.001_bib2","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.drugpo.2014.01.007","article-title":"Hepatitis C among people who inject drugs in Tbilisi, Georgia: an urgent need for prevention and treatment","volume":"25","author":"Bouscaillou","year":"2014","journal-title":"Int J. Drug Policy"},{"key":"10.1016\/j.antiviral.2017.12.001_bib3","unstructured":"Center for Disease Analysis report, available at: http:\/\/centerforda.com\/fact_files.htm (accessed at 1 July 2016)."},{"issue":"29","key":"10.1016\/j.antiviral.2017.12.001_bib4","first-page":"545","article-title":"Progress toward prevention and control of hepatitis C virus infection\u2013Egypt, 2001-2012","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"4","key":"10.1016\/j.antiviral.2017.12.001_bib5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jval.2016.01.010","article-title":"Economic and public health impacts of policies restricting access to hepatitis C treatment for Medicaid patients","volume":"19","author":"Chidi","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.antiviral.2017.12.001_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.12546","article-title":"Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case","author":"Deuffic-Burban","year":"2016","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2017.12.001_bib7","doi-asserted-by":"crossref","first-page":"g3308","DOI":"10.1136\/bmj.g3308","article-title":"Antiviral treatment of hepatitis C","volume":"348","author":"Feeney","year":"2014","journal-title":"BMJ"},{"issue":"1 Suppl. l","key":"10.1016\/j.antiviral.2017.12.001_bib8","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2017.12.001_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.antiviral.2015.01.004","article-title":"A path to eradication of hepatitis C in low- and middle-income countries","volume":"119","author":"Graham","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2017.12.001_bib10","series-title":"Euro Hepatitis Index 2012 Report","isbn-type":"print","author":"Health Consumer Powerhouse AB","year":"2012","ISBN":"https:\/\/id.crossref.org\/isbn\/9789198068702"},{"issue":"11","key":"10.1016\/j.antiviral.2017.12.001_bib11","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1136\/gutjnl-2014-308166","article-title":"Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?","volume":"64","author":"Innes","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2017.12.001_bib12","series-title":"The World Migration Report 2013: Migrant Well-being and Development - the 7th Report in IOM's World Migration Report Series","author":"International Organization for Migration","year":"2013"},{"issue":"5","key":"10.1016\/j.antiviral.2017.12.001_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002032","article-title":"Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis","volume":"13","author":"Iyengar","year":"2016","journal-title":"PLoS Med."},{"issue":"9","key":"10.1016\/j.antiviral.2017.12.001_bib14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/M14-1313","article-title":"The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection","volume":"162","author":"Linas","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.antiviral.2017.12.001_bib15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40261-016-0414-y","article-title":"Early treatment in HCV: is it a cost-utility option from the Italian perspective?","volume":"36","author":"Marcellusi","year":"2016","journal-title":"Clin. Drug Invest."},{"issue":"11","key":"10.1016\/j.antiviral.2017.12.001_bib16","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.cmi.2015.07.002","article-title":"Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe","volume":"21","author":"Ozaras","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"issue":"2","key":"10.1016\/j.antiviral.2017.12.001_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11524-006-9032-y","article-title":"Prevalence of hepatitis C, HIV, and risk behaviors for blood-borne infections: a population-based survey of the adult population of T'bilisi, Republic of Georgia","volume":"83","author":"Stvilia","year":"2006","journal-title":"J. Urban Health"},{"key":"10.1016\/j.antiviral.2017.12.001_bib18","unstructured":"Surveillance and prevention of hepatitis B and C in Europe. Technical report, available at: http:\/\/ecdc.europa.eu\/en\/healthtopics\/hepatitis_C\/Pages\/index.aspx#sthash.8hClPwH0.dpuf (accessed at 1 July 2016)."},{"issue":"9973","key":"10.1016\/j.antiviral.2017.12.001_bib19","first-page":"1124","article-title":"Dusheiko GM","volume":"385","author":"Webster","year":"2015","journal-title":"Hepatitis C. Lancet"},{"key":"10.1016\/j.antiviral.2017.12.001_bib20","unstructured":"WHO guidelines, available at: http:\/\/www.who.int\/hepatitis\/strategy2016-2021\/en (accessed at 1 July 2016)."},{"key":"10.1016\/j.antiviral.2017.12.001_bib21","unstructured":"World Bank classification of countries by economy, available at: http:\/\/data.worldbank.org\/about\/country-and-lending-groups (accessed at 1 July 2016)."},{"issue":"4","key":"10.1016\/j.antiviral.2017.12.001_bib22","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3855\/jidc.7849","article-title":"Barriers to access to hepatitis C treatment","volume":"10","author":"Yilmaz","year":"2016","journal-title":"J Infect Dev Ctries"},{"issue":"11","key":"10.1016\/j.antiviral.2017.12.001_bib23","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1136\/gutjnl-2015-310421","article-title":"Hepatitis C virus treatment in the real world: optimising treatment and access to therapies","volume":"64","author":"Zoulim","year":"2015","journal-title":"Gut"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216303874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216303874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T05:01:25Z","timestamp":1530075685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216303874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":23,"alternative-id":["S0166354216303874"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.12.001","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}